Hada Taira, Miyamoto Morikazu, Ishibashi Hiroki, Matsuura Hiroko, Sakamoto Takahiro, Kakimoto Soichiro, Iwahashi Hideki, Suzuki Rie, Tsuda Hitoshi, Takano Masashi
Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan.
Department of Pathology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan.
Mol Clin Oncol. 2021 Apr;14(4):75. doi: 10.3892/mco.2021.2237. Epub 2021 Feb 23.
The aim of the present study was to examine the clinical outcome of ovarian clear cell borderline tumor (CCBT) through pathological review for cases with clear cell carcinoma (CCC) and CCBT between 1984 and 2015 who received surgery at the National Defense Medical College Hospital using 2020 World Health Organization (WHO) criteria. In addition to the definition of CCBT in 2020 WHO criteria, clear cell with atypia of the glandular epithelium without fibromatous component was added to the diagnostic criteria of CCBT. Two cases with CCBT were identified through review in the current study. There were no cases that changed from the initial CCBT diagnosis that were included in the current study. Case 1 was a 43-year-old woman who received total hysterectomy, bilateral salpingo-oophorectomy and partial omentectomy. Pathologically, cysts were lined by cuboidal, hobnail and clear cells with eosinophilic cytoplasm and moderate nuclear atypia without the fibromatous component. These cells were adjacent to atypical endometriosis and non-atypical endometriosis, and the patient was diagnosed with CCBT. She exhibited no evidence of the disease for 37 months following surgery. Case 2 was a 42-year-old woman who received left salpingo-oophorectomy, partial omentectomy and pelvic lymphadenectomy. The tumor exhibited a cyst (80 mm) and nodular component. Pathologically, the tumor cells were lined by hobnail cells with mild atypia and eosinophilic cytoplasm without the fibromatous component. This patient was diagnosed with CCBT and exhibited no evidence of disease for 20 months following surgery. CCBT without fibromatous component is a rare and non-aggressive histological subtype. Additionally, regardless of fibromatous component, CCBT was able to be diagnosed.
本研究的目的是通过对1984年至2015年间在国防医科大学医院接受手术的透明细胞癌(CCC)和卵巢透明细胞交界性肿瘤(CCBT)病例进行病理复查,采用2020年世界卫生组织(WHO)标准来检查CCBT的临床结局。除了2020年WHO标准中CCBT的定义外,腺上皮具有非典型性的透明细胞且无纤维瘤成分也被纳入CCBT的诊断标准。通过本研究中的复查确定了2例CCBT病例。本研究中没有包括从最初CCBT诊断改变的病例。病例1是一名43岁女性,接受了全子宫切除术、双侧输卵管卵巢切除术和部分大网膜切除术。病理检查显示,囊肿内衬立方形、鞋钉样和透明细胞,细胞质嗜酸性,核中度异型,无纤维瘤成分。这些细胞与非典型子宫内膜异位症和非非典型子宫内膜异位症相邻,该患者被诊断为CCBT。术后37个月她没有疾病迹象。病例2是一名42岁女性,接受了左侧输卵管卵巢切除术、部分大网膜切除术和盆腔淋巴结清扫术。肿瘤表现为一个囊肿(80毫米)和结节成分。病理检查显示,肿瘤细胞由鞋钉样细胞内衬,有轻度异型性,细胞质嗜酸性,无纤维瘤成分。该患者被诊断为CCBT,术后20个月没有疾病迹象。无纤维瘤成分的CCBT是一种罕见且侵袭性较低的组织学亚型。此外,无论有无纤维瘤成分,CCBT均能够被诊断。